XML 20 R12.htm IDEA: XBRL DOCUMENT
v3.25.3

Notes Receivable, Net | 9 Months Ended
--- | ---
Sep. 30, 2025
Receivables [Abstract] |
Notes Receivable, net | Note 4 – Notes Receivable, net The Company’s notes receivable, net consists of investments in loans to buyers of charged-off and nonperforming receivable portfolios through HGC and financing of laboratory equipment sales through ALT. As of September 30, 2025 and December 31, 2024, the Company’s outstanding notes receivable balance related to loans to buyers of charged-off and nonperforming receivable portfolios, net of unamortized deferred fees and costs on originated loans, and adjusted for the allowance for credit losses was $8.9 million and $9.6 million, respectively. The activity during the nine months ended September 30, 2025 includes the additional investment in notes receivable of approximately $4.0 million, which was offset by principal payments made by borrowers of approximately $4.7 million. As of both September 30, 2025 and December 31, 2024, the Company’s outstanding notes receivable balance related to financing of laboratory equipment sales, net of unamortized deferred fees and costs on originated loans and adjusted for the reserve for credit losses was $0.4 million. The activity during the nine months ended September 30, 2025 includes the investment in notes receivable of approximately $0.4 million, which was offset by principal payments made by purchasers of $0.4 million and an immaterial amount of deferred financing fees, and allowance for credit losses. The table below shows the Company’s lending activity for the nine months ended September 30, 2025 (in thousands):
Notes receivable, net, December 31, 2024 |  | $ | 10,409 |
Investment in notes receivable |  |  | 4,433 |
Principal repayments |  |  | (5,132 | )
Notes receivable, as of September 30, 2025 |  |  | 9,710 |
Deferred financing fees and costs, net |  |  | (44 | )
Allowance for credit losses |  |  | (346 | )
Notes receivable, net, September 30, 2025 |  | $ | 9,320 |
In accordance with ASC 326, the Company performs a review of notes receivable on a quarterly basis. During the nine months ended September 30, 2025, the Company made no material changes to the provision for credit losses in selling, general and administrative expense on the consolidated statement of income. As of September 30, 2025 and December 31, 2024, the amortized cost basis of notes receivable in nonaccrual status was $4.8 million and $5.3 million, respectively.

X
- Definition The entire disclosure for financing receivable. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 12A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481933/310-10-55-12A Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-42 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 44 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-44 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/310-10/tableOfContent Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/310-20/tableOfContent + Details
Name: | us-gaap_FinancingReceivablesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ReceivablesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration